Archive for the ‘Clinical Trial Results’ Category

February 9, 2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

.   .   

This is a multicenter, randomized, controlled trial conducted at 31 French hospital. Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). During the observational phase, remission rates […]

No Comments Posted in Clinical Nephrology, Clinical Trial Results, Glomerulonephritis
February 9, 2017

The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death

.   .   

This is a retrospective cohort study of 2300 patients aged ≥18 years who initiated hemodialysis between 2004 and 2012 at five Canadian dialysis programs. The authors observed significantly lower mortality in individuals who underwent a predialysis fistula attempt than in those without a predialysis fistula attempt in patients aged <65 years and in the first […]

No Comments Posted in Chronic Kidney Disease, Clinical Nephrology, Clinical Trial Results, Hemodialysis, Vascular Access
February 9, 2017

DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease

.   .   

This trial looked Atherosclerosis Risk in Communities (ARIC) Study participants with baseline estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 (N = 14,882).  3,720 participants developed kidney disease during a median follow-up of 23 years. Participants with a DASH diet score in the lowest tertile were 16% more likely to develop kidney disease than those with the highest score tertile […]

1 Comment Posted in Clinical Nephrology, Clinical Trial Results, General Nephrology, Hypertension
November 19, 2016

Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

ASN 2016 High Impact Clinical Trial Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany. Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk […]

No Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Remote ischaemic preconditioning (RIPC) leads to sustained improvement in allograft function following live donor (LD) kidney transplantation: 5 year follow up in the REnal Protection Against Ischaemia Reperfusion in transplantation (REPAIR) study

ASN 2016 High Impact Clinical Trial Kristin Veighey, Jennifer Nicholas, Tim Clayton, Raymond Macallister Using 4 cycles of ischemia/reperfusion in the preoperative living donors, remote ischemic preconditioning (RIPC) was evaluated regarding its impact on post-tranplant outcomes.  The primary endpoint was iohexal GFR at 12 months and secondary endpoints were change in eGFR, graft loss or death. […]

No Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)

High Impact Clinical Trials ASN 2016 Howard Trachtman, Peter J. Nelson, Radko Komers In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria. As compared to irbesartan, urinary protein excretion was […]

2 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

AURA-LV: Successful Treatment of Active Lupus Nephritis with Voclosporin

ASN 2016 High Impact Clinical Trial William Franklin Pendergraft, James A. Tumlin, Brad H. Rovin, Mary Anne Dooley, David R.W. Jayne, David Wofsy, Frederic A. Houssiau, David Isenberg, Tak Mao Chan, Neil Solomons, Robert B. Huizinga In patients with biopsy proven lupus nephritis, complete remission at 24 weeks was reached by 32.6% (p = 0.045) […]

18 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

The Sodium Lowering in Dialysate (SoLID) Trial: A Randomised Controlled Trial of Low versus Standard Dialysate Sodium Concentration (DNa) during Hemodialysis (HD) for Regression of Left Ventricular (LV) Mass

ASN 2016 High Impact Clinical Trial Mark R. Marshall, Alain C. Vandal, Joanna Leigh Dunlop, Janak Rashme de Zoysa, Imad A. Haloob, Christopher J. Hood, John Irvine, Philip J. Matheson, David Mcgregor, Kannaiyan Samuel Rabindranath, David Semple. Auckland, New Zealand. Dialysate sodium (Na) concentration of 135 mmol/L vs 140 mmol/L did not effectively reduce left ventricular […]

1 Comment Posted in Clinical Trial Results, Conference Alert
November 19, 2016

ASN 2016 Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation: An Open-Label, Multicentre, Randomized Controlled Trial

High Impact Clinical Trial Session at the 2016 ASN Christian Hugo, Michael Sean Wiesener, Mirian Opgenoorth, Oliver Thomusch. Dresden, Germany In low-tacrolimus treated, immunologically low-risk renal transplant recipients, rapid steroid withdrawal is safe with no impact on survival or biopsy-proven acute rejection.  Post-transplantation diabetes incidence is reduced from 39.2% to 23.9%(Basiliximab) or 22.7% (rATG) in […]

No Comments Posted in Clinical Trial Results, Conference Alert
August 14, 2016

Past Decline Versus Current eGFR and Subsequent Mortality Risk

.   .   

This is an individual-level meta-analysis of the risk of mortality associated with antecedent eGFR slope among 1.2 million subjects within the CKD Prognosis Consortium. Over a 3-year antecedent period, compared with a slope of 0 ml/min per 1.73 m(2) per year, a slope of -6 ml/min per 1.73 m(2) per year was associated with adjusted hazard ratios for all-cause mortality of […]

No Comments Posted in Chronic Kidney Disease, Clinical Nephrology, Clinical Trial Results
August 14, 2016

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75Years: A Randomized Clinical Trial

.   .   

This is a  multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT) to determine the effects of intensive (<120 mm Hg) compared with standard (<140 mm Hg) SBP targets. The primary cardiovascular disease outcome was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in a myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascular causes. All-cause mortality […]

No Comments Posted in Clinical Trial Results, Hypertension
August 14, 2016

Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit

.   .   

   This multicenter randomized trial assigned 620 ICU patients with severe stages 1-3 AKI with either an early dialysis start (at randomization) or late dialysis start (a classic indication to initiate).  The primary outcome was survival at day 60.  There was no survival difference between the groups at day 60; 150 deaths occurred among 311 […]

No Comments Posted in Acute Kidney Injury, Clinical Nephrology, Clinical Trial Results
August 14, 2016

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

.   .   

  This randomized control trial of over 4000 high risk patients with Type 2 diabetes and eGFR > 30 ml/min, empagliflozin (a sodium-glucose cotransporter 2 inhibitor) when compared with placebo was associated with slower progression of kidney disease (12.7% vs 18.8% for worsening nephropathy and 1.5% vs 2.6% for doubling of serum creatinine) when added to the standard of care.  […]

No Comments Posted in Chronic Kidney Disease, Clinical Nephrology, Clinical Trial Results, Diabetes, General Nephrology